两种剂量碘帕醇对肝脏CT增强扫描效果的影响  

Effect of two different doses of iopamidol enhancement on liver CT

作　　者：周芳彬[1] 余杰[1] 

机构地区：[1]丽水市人民医院放射科,浙江丽水323000

出　　处：《中国生化药物杂志》2017年第8期237-238,共2页Chinese Journal of Biochemical Pharmaceutics

摘　　要：目的 探讨和分析两种剂量碘帕醇对肝脏CT增强扫描效果的影响。方法 选取丽水市人民医院在2014年1月-2016年8月期间接受肝脏增强扫描的80例患者为本研究对象,将所有的患者按照随机数字表法分为2组,包括研究组和对照组,每组40例。对照组患者在进行肝脏CT增强扫描时采用浓度为300 g/L剂量为1.5 mL/kg的碘帕醇作为对比剂增强扫描,研究组患者在实施肝脏CT增强扫描时采用浓度为300 g/L剂量为1.2 mL/kg的碘帕醇作为对比剂增强扫描,观察和对比2组患者的增强效果。结果 研究组的动脉期成像质量与门静脉期的成像质量均优于对照组,2组之间差异具有统计学意义。研究组不良反应多于对照组,2组间差异具有统计学意义（P〈0.05）。结论 使用剂量为1.5 mL/kg的碘帕醇作为对比剂增强扫描中的增强效果明显的优于剂量为1.2 mL/kg的碘帕醇,提高扫描效果的同时也增加不良反应。Objective To investigate and analyze the effect of two different doses of iopamidol enhancement on hepatic CT. Methods In Lishui people＆#39;s hospital from January 2014 to August 201680 patients who accept hepatic enhancement scan were randomly divided into two groups, the study group and the control group, 40 cases in each group. The control group were received liver CT scan with iopamidol as contrast agent, the concentration was 300 g/L, the dosage was 1.5mL/kg, the concentration and dosage in the study group was respectively 300g/L and 1.2mL/kg. The enhancement effect after scanning in the two groups were observed and compared. Results The imaging quality in arterial phase and in portal phase in the study group were better than those in the control group （P〈0.05）; The adverse reactions in the study group were more than those in the control group, the difference between the two groups was statistically significant（P〈0.05）. Conclusion In liver CT scanning process, iopamidol as the contrast agent, the enhancement effect of 1.5mL/kg of iopamidol is better than 1.2mL/kg of iopamidol, but the efficiency scanning effect is improved at will also increase allergies and other adverse reactions..

关 键 词：增强扫描 碘帕醇 

分 类 号：R445.3[医药卫生—影像医学与核医学]